{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:41:19Z","timestamp":1772120479415,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Korea Institute of Science and Technology, Republic of Korea","award":["2Z04850"],"award-info":[{"award-number":["2Z04850"]}]},{"name":"Sookmyung Women's University Research Grants","award":["1-1403-0042"],"award-info":[{"award-number":["1-1403-0042"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.cbi.2017.02.014","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T22:00:25Z","timestamp":1487973625000},"page":"24-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Antidiabetic effect of SN158 through PPAR\u03b1\/\u03b3 dual activation in ob\/ob mice"],"prefix":"10.1016","volume":"268","author":[{"given":"Yujung","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongkai","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Hoon","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyu-Un","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li Tai","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6761","authenticated-orcid":false,"given":"Yong Kee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Nam","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2017.02.014_bib1","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1161\/01.CIR.0000163655.15190.FB","article-title":"America's children: a critical time for prevention","volume":"111","author":"Eckel","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cbi.2017.02.014_bib2","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1210\/en.2003-0288","article-title":"Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors","volume":"144","author":"Lee","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.cbi.2017.02.014_bib3","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1021\/cr2001355","article-title":"PPARs and lipid ligands in inflammation and metabolism","volume":"111","author":"Harmon","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.cbi.2017.02.014_bib4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00018-003-3216-3","article-title":"Peroxisome proliferator-activated receptor alpha target genes","volume":"61","author":"Mandard","year":"2004","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.cbi.2017.02.014_bib5","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.beem.2007.09.004","article-title":"PPAR agonists: multimodal drugs for the treatment of type-2 diabetes","volume":"21","author":"Gross","year":"2007","journal-title":"Best. Pract. Res. Cl. En."},{"key":"10.1016\/j.cbi.2017.02.014_bib6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.2337\/diabetes.54.2.582","article-title":"Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes","volume":"54","author":"Flavell","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.cbi.2017.02.014_bib7","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2337\/db06-1110","article-title":"Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes - the STOP-NIDDM trial","volume":"56","author":"Andrulionyte","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.cbi.2017.02.014_bib8","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1021\/jm9804127","article-title":"N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents","volume":"41","author":"Henke","year":"1998","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.cbi.2017.02.014_bib9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00125-014-3456-9","article-title":"Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis","volume":"58","author":"Levin","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.cbi.2017.02.014_bib10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cbi.2017.02.014_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cbi.2017.02.014_bib12","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbalip.2007.02.003","article-title":"Safety issues and prospects for future generations of PPAR modulators","volume":"1771","author":"Rubenstrunk","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cbi.2017.02.014_bib13","doi-asserted-by":"crossref","first-page":"9530","DOI":"10.1038\/srep09530","article-title":"Identification of a novel selective agonist of PPARgamma with no promotion of adipogenesis and less inhibition of osteoblastogenesis","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cbi.2017.02.014_bib14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2362.2005.01456.x","article-title":"Peroxisome proliferator-activated receptor gamma: the more the merrier?","volume":"35","author":"Argmann","year":"2005","journal-title":"Eur. J. Clin. Invest"},{"key":"10.1016\/j.cbi.2017.02.014_bib15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/sj.embor.7400082","article-title":"Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm","volume":"5","author":"Cock","year":"2004","journal-title":"EMBO Rep."},{"key":"10.1016\/j.cbi.2017.02.014_bib16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/bkcs.10662","article-title":"A\u00a0novel partial PPAR alpha\/gamma dual agonist SN159 improves insulin sensitivity","volume":"37","author":"Jung","year":"2016","journal-title":"Bull. Korean Chem. Soc."},{"key":"10.1016\/j.cbi.2017.02.014_bib17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.cbi.2017.02.014_bib18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejphar.2012.03.033","article-title":"NS-1: a novel partial peroxisome proliferator-activated receptor gamma agonist to improve insulin sensitivity and metabolic profile","volume":"684","author":"Chaudhary","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.cbi.2017.02.014_bib19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bbrc.2013.01.083","article-title":"Anti-diabetic effect of amorphastilbol through PPARalpha\/gamma dual activation in db\/db mice","volume":"432","author":"Lee","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cbi.2017.02.014_bib20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.coph.2006.06.009","article-title":"PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome","volume":"6","author":"Fievet","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.cbi.2017.02.014_bib21","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1016\/j.bmcl.2011.04.057","article-title":"Design, synthesis, and evaluation of bromo-retrochalcone derivatives as protein tyrosine phosphatase 1B inhibitors","volume":"21","author":"Liu","year":"2011","journal-title":"Bioorg Med. Chem. Lett."},{"key":"10.1016\/j.cbi.2017.02.014_bib22","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1016\/j.febslet.2008.09.011","article-title":"Sargaquinoic acid and sargahydroquinoic acid from Sargassum yezoense stimulate adipocyte differentiation through PPARalpha\/gamma activation in 3T3-L1 cells","volume":"582","author":"Kim","year":"2008","journal-title":"FEBS Lett."},{"key":"10.1016\/j.cbi.2017.02.014_bib23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3892\/ijmm.2015.2227","article-title":"Amorphastilbol exerts beneficial effects on glucose and lipid metabolism in mice consuming a high-fat-diet","volume":"36","author":"Lee","year":"2015","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.cbi.2017.02.014_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2165\/11539500-000000000-00000","article-title":"Therapeutic potential of aleglitazar, a new dual PPAR-alpha\/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus","volume":"10","author":"Cavender","year":"2010","journal-title":"Am. J. Cardiovasc Drugs"},{"key":"10.1016\/j.cbi.2017.02.014_bib25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.tips.2005.03.003","article-title":"PPARs: therapeutic targets for metabolic disease","volume":"26","author":"Berger","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.cbi.2017.02.014_bib26","series-title":"Potent Anti-diabetic Actions of a Novel Non-agonist PPARgamma Ligand that Blocks Cdk5-mediated Phosphorylation, Probe Reports from the NIH Molecular Libraries Program","author":"Kamenecka","year":"2010"},{"key":"10.1016\/j.cbi.2017.02.014_bib27","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nature13887","article-title":"An ERK\/Cdk5 axis controls the diabetogenic actions of PPARgamma","volume":"517","author":"Banks","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.cbi.2017.02.014_bib28","doi-asserted-by":"crossref","first-page":"26618","DOI":"10.1074\/jbc.M114.566794","article-title":"A\u00a0novel non-agonist peroxisome proliferator-activated receptor gamma (PPARgamma) ligand UHC1 blocks PPARgamma phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity","volume":"289","author":"Choi","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.cbi.2017.02.014_bib29","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc07-2270","article-title":"Rosiglitazone-associated fractures in type 2 diabetes - an analysis from a diabetes outcome progression trial (ADOPT)","volume":"31","author":"Kahn","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cbi.2017.02.014_bib30","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1161\/01.CIR.0000103683.99399.7E","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003","volume":"108","author":"Nesto","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cbi.2017.02.014_bib31","doi-asserted-by":"crossref","first-page":"32696","DOI":"10.1155\/2007\/32696","article-title":"Selective modulators of PPAR-gamma activity: molecular aspects related to obesity and side-effects","volume":"2007","author":"Zhang","year":"2007","journal-title":"PPAR Res."},{"key":"10.1016\/j.cbi.2017.02.014_bib32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev.nutr.20.1.365","article-title":"Molecular mechanisms regulating hormone-sensitive lipase and lipolysis","volume":"20","author":"Holm","year":"2000","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.cbi.2017.02.014_bib33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev.med.53.082901.104057","article-title":"Lipotoxic diseases","volume":"53","author":"Unger","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.cbi.2017.02.014_bib34","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1210\/me.2002-0217","article-title":"Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator","volume":"17","author":"Berger","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.cbi.2017.02.014_bib35","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1097-2765(01)00353-7","article-title":"A\u00a0unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity","volume":"8","author":"Rocchi","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cbi.2017.02.014_bib36","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0026-0495(00)90440-2","article-title":"The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db\/db mice,","volume":"49","author":"Shimaya","year":"2000","journal-title":"Metabolism"}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279717302004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279717302004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T13:42:29Z","timestamp":1757857349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279717302004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":36,"alternative-id":["S0009279717302004"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2017.02.014","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727552139.793548265","asserted-by":"object"}]},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidiabetic effect of SN158 through PPAR\u03b1\/\u03b3 dual activation in ob\/ob mice","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2017.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}